
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6819682/publications.pdf Version: 2024-02-01



DANIEL I RADER

#	Article	IF	CITATIONS
1	Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine, 2004, 350, 1495-1504.	27.0	4,527
2	Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010, 466, 707-713.	27.8	3,249
3	Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013, 45, 1274-1283.	21.4	2,641
4	A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease. Nature Genetics, 2015, 47, 1121-1130.	21.4	2,054
5	Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet, The, 2012, 380, 572-580.	13.7	1,937
6	Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis. New England Journal of Medicine, 2011, 364, 127-135.	27.0	1,686
7	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011, 43, 333-338.	21.4	1,685
8	A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction. Science, 2007, 316, 1491-1493.	12.6	1,485
9	Large-scale association analysis identifies new risk loci for coronary artery disease. Nature Genetics, 2013, 45, 25-33.	21.4	1,439
10	From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature, 2010, 466, 714-719.	27.8	1,018
11	Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nature Genetics, 2009, 41, 334-341.	21.4	990
12	New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport. Circulation Research, 2005, 96, 1221-1232.	4.5	901
13	Cholesteryl Ester Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 160-167.	2.4	780
14	Cholesterol Efflux and Atheroprotection. Circulation, 2012, 125, 1905-1919.	1.6	772
15	Common variants associated with plasma triglycerides and risk for coronary artery disease. Nature Genetics, 2013, 45, 1345-1352.	21.4	754
16	Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol. New England Journal of Medicine, 2004, 350, 1505-1515.	27.0	743
17	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. Journal of the American College of Cardiology, 2016, 67, 2578-2589.	2.8	723
18	Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nature Genetics, 2009, 41, 342-347.	21.4	709

#	Article	IF	CITATIONS
19	Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet, The, 2012, 379, 1205-1213.	13.7	668
20	Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 211-221.	27.0	633
21	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, The, 2013, 381, 40-46.	13.7	624
22	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. New England Journal of Medicine, 2017, 376, 1933-1942.	27.0	593
23	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature, 2015, 518, 102-106.	27.8	581
24	A Protein-Truncating <i>HSD17B13</i> Variant and Protection from Chronic Liver Disease. New England Journal of Medicine, 2018, 378, 1096-1106.	27.0	556
25	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	21.4	552
26	NARC-1/PCSK9 and Its Natural Mutants. Journal of Biological Chemistry, 2004, 279, 48865-48875.	3.4	544
27	HDL and cardiovascular disease. Lancet, The, 2014, 384, 618-625.	13.7	540
28	The Agenda for Familial Hypercholesterolemia. Circulation, 2015, 132, 2167-2192.	1.6	539
29	Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia. New England Journal of Medicine, 2007, 356, 148-156.	27.0	504
30	Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. Journal of Clinical Investigation, 2007, 117, 2216-2224.	8.2	498
31	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nature Genetics, 2018, 50, 1514-1523.	21.4	497
32	Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nature Medicine, 1998, 4, 1189-1192.	30.7	496
33	The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. Journal of Lipid Research, 2009, 50, S189-S194.	4.2	488
34	Macrophage Reverse Cholesterol Transport. Circulation, 2006, 113, 2548-2555.	1.6	485
35	Molecular regulation of HDL metabolism and function: implications for novel therapies. Journal of Clinical Investigation, 2006, 116, 3090-3100.	8.2	480
36	Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature, 1993, 365, 65-69.	27.8	472

#	Article	IF	CITATIONS
37	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	21.4	470
38	Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet, The, 2011, 377, 383-392.	13.7	466
39	A novel endothelial-derived lipase that modulates HDL metabolism. Nature Genetics, 1999, 21, 424-428.	21.4	461
40	Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nature Genetics, 2020, 52, 680-691.	21.4	445
41	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science, 2016, 351, 1166-1171.	12.6	438
42	Translating molecular discoveries into new therapies for atherosclerosis. Nature, 2008, 451, 904-913.	27.8	436
43	Coding Variation in <i>ANGPTL4,LPL,</i> and <i>SVEP1</i> and the Risk of Coronary Disease. New England Journal of Medicine, 2016, 374, 1134-1144.	27.0	427
44	The Metabolic Syndrome. Circulation, 2003, 108, 1546-1551.	1.6	422
45	Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. Journal of Clinical Investigation, 2003, 111, 1795-1803.	8.2	421
46	Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo. Circulation, 2003, 108, 661-663.	1.6	403
47	COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice. Science, 2004, 306, 1954-1957.	12.6	403
48	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2015, 3, 507-513.	11.4	389
49	Clinical Genetic Testing for FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2018, 72, 662-680.	2.8	387
50	Inactivating Mutations in <i>NPC1L1</i> and Protection from Coronary Heart Disease. New England Journal of Medicine, 2014, 371, 2072-2082.	27.0	386
51	Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2264-2276.	2.4	369
52	Regression of Atherosclerosis Induced by Liver-Directed Gene Transfer of Apolipoprotein A-I in Mice. Circulation, 1999, 100, 1816-1822.	1.6	352
53	The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 796-801.	2.4	348
54	ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. Journal of the American College of Cardiology, 2017, 69, 2054-2063.	2.8	348

#	Article	IF	CITATIONS
55	Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nature Communications, 2019, 10, 1499.	12.8	346
56	Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In Vivo. Circulation, 2006, 113, 90-97.	1.6	344
57	A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nature Genetics, 2006, 38, 68-74.	21.4	339
58	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated RiskÂofÂCardiovascular Disease and AorticÂStenosis. Journal of the American College of Cardiology, 2018, 71, 177-192.	2.8	337
59	Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell, 2021, 184, 1858-1864.e10.	28.9	332
60	The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nature Medicine, 2004, 10, 966-973.	30.7	318
61	Gene Transfer and Hepatic Overexpression of the HDL Receptor SR-BI Reduces Atherosclerosis in the Cholesterol-Fed LDL Receptor–Deficient Mouse. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 721-727.	2.4	317
62	Shared Genetic Susceptibility to Ischemic Stroke and Coronary Artery Disease. Stroke, 2014, 45, 24-36.	2.0	302
63	Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature, 2017, 544, 235-239.	27.8	292
64	Genome-Wide Association Study of Coronary Heart Disease and Its Risk Factors in 8,090 African Americans: The NHLBI CARe Project. PLoS Genetics, 2011, 7, e1001300.	3.5	290
65	Association of Low-Frequency and Rare Coding-Sequence Variants with Blood Lipids and Coronary Heart Disease in 56,000 Whites and Blacks. American Journal of Human Genetics, 2014, 94, 223-232.	6.2	287
66	Characterization of the lipolytic activity of endothelial lipase. Journal of Lipid Research, 2002, 43, 921-929.	4.2	277
67	High-density lipoproteins: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2013, 7, 484-525.	1.5	276
68	Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. Journal of Clinical Investigation, 2005, 115, 2870-2874.	8.2	269
69	Increased Formation of Distinct F ₂ Isoprostanes in Hypercholesterolemia. Circulation, 1998, 98, 2822-2828.	1.6	266
70	Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. Journal of Lipid Research, 2008, 49, 1344-1352.	4.2	266
71	The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. Journal of Clinical Investigation, 2001, 108, 1031-1040.	8.2	264
72	Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nature Genetics, 2017, 49, 1113-1119.	21.4	260

#	Article	IF	CITATIONS
73	Effect of Insulin Resistance, Dyslipidemia, and Intra-abdominal Adiposity on the Development of Cardiovascular Disease and Diabetes Mellitus. American Journal of Medicine, 2007, 120, S12-S18.	1.5	254
74	ls it time to revise the HDL cholesterol hypothesis?. Nature Medicine, 2012, 18, 1344-1346.	30.7	241
75	Characterization of the lipolytic activity of endothelial lipase. Journal of Lipid Research, 2002, 43, 921-9.	4.2	234
76	Inflammatory Markers of Coronary Risk. New England Journal of Medicine, 2000, 343, 1179-1182.	27.0	232
77	Beyond High-Density Lipoprotein Cholesterol Levels. Journal of the American College of Cardiology, 2008, 51, 2199-2211.	2.8	231
78	Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2730-2735.	7.1	229
79	Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1057-1064.	2.4	228
80	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. American Journal of Human Genetics, 2012, 91, 823-838.	6.2	227
81	Absence of 12/15-Lipoxygenase Expression Decreases Lipid Peroxidation and Atherogenesis in Apolipoprotein E–Deficient Mice. Circulation, 2001, 103, 2277-2282.	1.6	225
82	Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. Journal of Clinical Investigation, 2003, 111, 1795-1803.	8.2	225
83	Lomitapide and Mipomersen. Circulation, 2014, 129, 1022-1032.	1.6	223
84	Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. Journal of Lipid Research, 2005, 46, 2023-2028.	4.2	220
85	Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nature Genetics, 2017, 49, 1450-1457.	21.4	218
86	Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated WithÂCoronary ArteryÂDisease. Journal of the American College of Cardiology, 2017, 69, 823-836.	2.8	214
87	Trials and Tribulations of CETP Inhibitors. Circulation Research, 2018, 122, 106-112.	4.5	210
88	Guggulipid for the Treatment of Hypercholesterolemia. JAMA - Journal of the American Medical Association, 2003, 290, 765.	7.4	205
89	Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. Journal of Clinical Investigation, 2003, 111, 357-362.	8.2	197
90	Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. Journal of Clinical Investigation, 2016, 126, 1323-1336.	8.2	196

#	Article	IF	CITATIONS
91	Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. Journal of Clinical Investigation, 2012, 122, 2807-2816.	8.2	190
92	Quantitation of Plasma Apolipoproteins in the Primary and Secondary Prevention of Coronary Artery Disease. Annals of Internal Medicine, 1994, 120, 1012.	3.9	187
93	Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nature Genetics, 2010, 42, 692-697.	21.4	181
94	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. Circulation, 2017, 135, 2494-2504.	1.6	180
95	Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nature Medicine, 2019, 25, 1274-1279.	30.7	177
96	Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature, 2022, 607, 97-103.	27.8	174
97	Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet, The, 2015, 386, 452-460.	13.7	173
98	Update on strategies to increase HDL quantity and function. Nature Reviews Cardiology, 2009, 6, 455-463.	13.7	172
99	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States. Circulation: Cardiovascular Genetics, 2016, 9, 240-249.	5.1	170
100	Regulation of reverse cholesterol transport and clinical implications. American Journal of Cardiology, 2003, 92, 42-49.	1.6	168
101	Increased Atherosclerosis in Mice Lacking Apolipoprotein A-I Attributable to Both Impaired Reverse Cholesterol Transport and Increased Inflammation. Circulation Research, 2005, 97, 763-771.	4.5	165
102	Laboratory Assessment of HDL Heterogeneity and Function. Clinical Chemistry, 2008, 54, 788-800.	3.2	164
103	Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. Journal of Clinical Investigation, 2009, 119, 1042-50.	8.2	162
104	Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 182-188.	2.4	160
105	Cardiovascular Protection by ApoE and ApoE-HDL Linked to Suppression of ECM Gene Expression and Arterial Stiffening. Cell Reports, 2012, 2, 1259-1271.	6.4	159
106	Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nature Genetics, 2019, 51, 1574-1579.	21.4	152
107	Overexpression of Secretory Phospholipase A2 Causes Rapid Catabolism and Altered Tissue Uptake of High Density Lipoprotein Cholesteryl Ester and Apolipoprotein A-I. Journal of Biological Chemistry, 2000, 275, 10077-10084.	3.4	149
108	Macrophage Sortilin Promotes LDL Uptake, Foam Cell Formation, and Atherosclerosis. Circulation Research, 2015, 116, 789-796.	4.5	149

#	Article	IF	CITATIONS
109	CXCL16 Is a Marker of Inflammation, Atherosclerosis, and Acute Coronary Syndromes in Humans. Journal of the American College of Cardiology, 2007, 49, 442-449.	2.8	148
110	Endothelial Lipase Concentrations Are Increased in Metabolic Syndrome and Associated with Coronary Atherosclerosis. PLoS Medicine, 2005, 3, e22.	8.4	147
111	Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia. American Journal of Cardiology, 2008, 102, 1438-1443.	1.6	146
112	Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1706-1713.	2.4	141
113	Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. Journal of Lipid Research, 1999, 40, 2134-2139.	4.2	139
114	Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. Cell Stem Cell, 2017, 20, 558-570.e10.	11.1	138
115	Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing. JAMA - Journal of the American Medical Association, 2017, 318, 381.	7.4	138
116	Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 624-630.	2.4	137
117	Novel HDL-directed pharmacotherapeutic strategies. Nature Reviews Cardiology, 2011, 8, 266-277.	13.7	136
118	Expression of Cholesteryl Ester Transfer Protein in Mice Promotes Macrophage Reverse Cholesterol Transport. Circulation, 2007, 116, 1267-1273.	1.6	135
119	Identification of Genetic Variants in Endothelial Lipase in Persons With Elevated High-Density Lipoprotein Cholesterol. Circulation, 2002, 106, 1321-1326.	1.6	130
120	Dose-Dependent Acceleration of High-Density Lipoprotein Catabolism by Endothelial Lipase. Circulation, 2003, 108, 2121-2126.	1.6	130
121	Sequencing of 640,000 exomes identifies <i>GPR75</i> variants associated with protection from obesity. Science, 2021, 373, .	12.6	130
122	Obesity and Atherogenic Dyslipidemia. Gastroenterology, 2007, 132, 2181-2190.	1.3	129
123	Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. Journal of Lipid Research, 2011, 52, 361-373.	4.2	129
124	Clinical and Laboratory Findings in the Oculocerebrorenal Syndrome of Lowe, with Special Reference to Growth and Renal Function. New England Journal of Medicine, 1991, 324, 1318-1325.	27.0	127
125	Trib1 is a lipid- and myocardial infarction–associated gene that regulates hepatic lipogenesis and VLDL production in mice. Journal of Clinical Investigation, 2010, 120, 4410-4414.	8.2	127
126	Lipoproteins, macrophage function, and atherosclerosis: Beyond the foam cell?. Cell Metabolism, 2005, 1, 223-230.	16.2	125

#	Article	IF	CITATIONS
127	Illuminating HDL — Is It Still a Viable Therapeutic Target?. New England Journal of Medicine, 2007, 357, 2180-2183.	27.0	121
128	SARS-CoV-2 seroprevalence among parturient women in Philadelphia. Science Immunology, 2020, 5, .	11.9	121
129	Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity. Journal of Clinical Investigation, 2017, 127, 2407-2417.	8.2	121
130	Human Secretory Phospholipase A2Mediates Decreased Plasma Levels of HDL Cholesterol and ApoA-I in Response to Inflammation in Human ApoA-I Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1213-1218.	2.4	117
131	Hepatic Proprotein Convertases Modulate HDL Metabolism. Cell Metabolism, 2007, 6, 129-136.	16.2	117
132	Endothelial Cells Secrete Triglyceride Lipase and Phospholipase Activities in Response to Cytokines as a Result of Endothelial Lipase. Circulation Research, 2003, 92, 644-650.	4.5	115
133	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	2.8	115
134	High-density lipoproteins and atherosclerosis. American Journal of Cardiology, 2002, 90, 62-70.	1.6	110
135	Tissue-Specific Liver X Receptor Activation Promotes Macrophage Reverse Cholesterol Transport In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 781-786.	2.4	107
136	The Anti-Oxidative Capacity of High-Density Lipoprotein Is Reduced in Acute Coronary Syndrome But Not in Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 2068-2075.	2.8	105
137	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. Journal of the American College of Cardiology, 2015, 66, 2201-2210.	2.8	105
138	Molecular regulation of macrophage reverse cholesterol transport. Current Opinion in Cardiology, 2007, 22, 368-372.	1.8	104
139	The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. Journal of the American College of Cardiology, 2008, 51, 1653-1662.	2.8	104
140	Rapid Regression of Atherosclerosis Induced by Liver-Directed Gene Transfer of ApoE in ApoE-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2162-2170.	2.4	103
141	Endogenously Produced Endothelial Lipase Enhances Binding and Cellular Processing of Plasma Lipoproteins via Heparan Sulfate Proteoglycan-mediated Pathway. Journal of Biological Chemistry, 2003, 278, 34331-34338.	3.4	103
142	Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents. Cell Metabolism, 2016, 24, 234-245.	16.2	103
143	Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression. Science Translational Medicine, 2012, 4, 148ra115.	12.4	102
144	Update on the Role of Endothelial Lipase in High-Density Lipoprotein Metabolism, Reverse Cholesterol Transport, and Atherosclerosis. Circulation Journal, 2010, 74, 2263-2270.	1.6	100

DANIEL J RADER

#	Article	IF	CITATIONS
145	A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14623-14628.	7.1	98
146	Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants. Circulation, 2019, 140, 42-54.	1.6	97
147	Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. Nature Genetics, 2022, 54, 382-392.	21.4	97
148	Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. Journal of Clinical Investigation, 2012, 122, 1677-1687.	8.2	96
149	Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport. Circulation, 2006, 113, 1140-1150.	1.6	93
150	Future Therapeutic Directions in Reverse Cholesterol Transport. Current Atherosclerosis Reports, 2010, 12, 73-81.	4.8	93
151	Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. American Journal of Cardiology, 2001, 87, 476-479.	1.6	92
152	A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia. Cell Stem Cell, 2017, 20, 478-489.e5.	11.1	92
153	Proprotein Covertases Are Responsible for Proteolysis and Inactivation of Endothelial Lipase. Journal of Biological Chemistry, 2005, 280, 36551-36559.	3.4	91
154	Apolipoprotein A-I Deficiency Results in Markedly Increased Atherosclerosis in Mice Lacking the LDL Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1914-1920.	2.4	90
155	Endothelial lipase colon; a new member of the triglyceride lipase gene family. Current Opinion in Lipidology, 2000, 11, 141-147.	2.7	89
156	Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. American Journal of Cardiology, 2003, 91, 18-23.	1.6	89
157	A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nature Medicine, 2017, 23, 1086-1094.	30.7	88
158	Lecithin: Cholesterol Acyltransferase Expression Has Minimal Effects on Macrophage Reverse Cholesterol Transport In Vivo. Circulation, 2009, 120, 160-169.	1.6	87
159	Exome Sequencing and Directed Clinical Phenotyping Diagnose Cholesterol Ester Storage Disease Presenting as Autosomal Recessive Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2909-2914.	2.4	87
160	HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics. Current Cardiology Reports, 2017, 19, 132.	2.9	85
161	High-Density Lipoprotein Hydrolysis by Endothelial Lipase Activates PPARα. Circulation Research, 2006, 98, 490-498.	4.5	84
162	Tribbles-1 regulates hepatic lipogenesis through posttranscriptional regulation of C/EBPα. Journal of Clinical Investigation, 2015, 125, 3809-3818.	8.2	84

#	Article	IF	CITATIONS
163	High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1515-1519.	2.4	83
164	The triglyceride–high-density lipoprotein axis: An important target of therapy?. American Heart Journal, 2004, 148, 211-221.	2.7	82
165	Genetic-Variation-Driven Gene-Expression Changes Highlight Genes with Important Functions for Kidney Disease. American Journal of Human Genetics, 2017, 100, 940-953.	6.2	81
166	Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis, 2018, 268, 196-206.	0.8	81
167	Knockdown of Acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 97-104.	2.4	79
168	Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production. Journal of Lipid Research, 2006, 47, 2297-2305.	4.2	78
169	Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program. Circulation, 2020, 142, 1633-1646.	1.6	78
170	Lipases and HDL metabolism. Trends in Endocrinology and Metabolism, 2002, 13, 174-178.	7.1	77
171	Sortilin and lipoprotein metabolism. Current Opinion in Lipidology, 2014, 25, 350-357.	2.7	76
172	Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 560-565.	2.4	74
173	TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis. Nature, 2016, 535, 303-307.	27.8	72
174	Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. American Journal of Human Genetics, 2021, 108, 1350-1355.	6.2	72
175	Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. Journal of Clinical Investigation, 2015, 125, 3819-3830.	8.2	72
176	Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. Journal of Clinical Investigation, 2010, 120, 2889-2899.	8.2	71
177	Dense Genotyping of Candidate Gene Loci Identifies Variants Associated With High-Density Lipoprotein Cholesterol. Circulation: Cardiovascular Genetics, 2011, 4, 145-155.	5.1	71
178	The Addition of Niacin to Statin Therapy Improves High-Density Lipoprotein Cholesterol Levels ButÂNot Metrics of Functionality. Journal of the American College of Cardiology, 2013, 62, 1909-1910.	2.8	71
179	mTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion. Journal of Clinical Investigation, 2017, 127, 4207-4215.	8.2	71
180	Impact of Combined Deficiency of Hepatic Lipase and Endothelial Lipase on the Metabolism of Both High-Density Lipoproteins and Apolipoprotein B–Containing Lipoproteins. Circulation Research, 2010, 107, 357-364.	4.5	70

#	Article	IF	CITATIONS
181	Gene Therapy in a Humanized Mouse Model of Familial Hypercholesterolemia Leads to Marked Regression of Atherosclerosis. PLoS ONE, 2010, 5, e13424.	2.5	69
182	Approach to the Patient with Extremely Low HDL-Cholesterol. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3399-3407.	3.6	69
183	ABC1: connecting yellow tonsils, neuropathy, and very low HDL. Journal of Clinical Investigation, 1999, 104, 1015-1017.	8.2	69
184	Effects of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib on Apolipoprotein B100 Metabolism in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1350-1356.	2.4	68
185	Effect of interleukin 1β inhibition in cardiovascular disease. Current Opinion in Lipidology, 2012, 23, 548-553.	2.7	68
186	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nature Genetics, 2022, 54, 761-771.	21.4	68
187	Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. American Journal of Cardiology, 2003, 91, 20-23.	1.6	67
188	Endothelial Lipase Promotes the Catabolism of ApoB-Containing Lipoproteins. Circulation Research, 2004, 94, 1554-1561.	4.5	67
189	New Therapeutic Approaches to the Treatment of Dyslipidemia. Cell Metabolism, 2016, 23, 405-412.	16.2	67
190	Differential Association of Plasma Angiopoietin-Like Proteins 3 and 4 With Lipid and Metabolic Traits. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1057-1063.	2.4	66
191	Apolipoprotein A-II Production Rate Is a Major Factor Regulating the Distribution of Apolipoprotein A-I Among HDL Subclasses LpA-I and LpA-I:A-II in Normolipidemic Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 306-312.	2.4	65
192	Adeno-Associated Virus Serotype 8 Gene Therapy Leads to Significant Lowering of Plasma Cholesterol Levels in Humanized Mouse Models of Homozygous and Heterozygous Familial Hypercholesterolemia. Human Gene Therapy, 2013, 24, 19-26.	2.7	65
193	Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovascular Diabetology, 2007, 6, 15.	6.8	64
194	Both the Peroxisome Proliferatorâ€Activated Receptor δAgonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDLâ€Đerived Cholesterol. Clinical and Translational Science, 2009, 2, 127-133.	3.1	64
195	Prolonged Correction of Hyperlipidemia in Mice with Familial Hypercholesterolemia Using an Adeno-Associated Viral Vector Expressing Very-Low-Density Lipoprotein Receptor. Molecular Therapy, 2000, 2, 256-261.	8.2	63
196	Biliary Sterol Secretion Is Required for Functional In Vivo Reverse Cholesterol Transport in Mice. Gastroenterology, 2011, 140, 1043-1051.	1.3	63
197	Biomarkers of Calcific Aortic Valve Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 623-632.	2.4	63
198	Future of Cholesteryl Ester Transfer Protein Inhibitors. Annual Review of Medicine, 2014, 65, 385-403.	12.2	62

#	Article	IF	CITATIONS
199	Pharmacologic Suppression of Hepatic ATP-Binding Cassette Transporter 1 Activity in Mice Reduces High-Density Lipoprotein Cholesterol Levels but Promotes Reverse Cholesterol Transport. Circulation, 2011, 124, 1382-1390.	1.6	61
200	Triglyceride-Rich Lipoproteins and Coronary Artery Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, e3-9.	2.4	61
201	Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 Diabetics. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1880-1888.	2.4	60
202	ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1753-1759.	2.4	60
203	Mechanisms of Disease: HDL metabolism as a target for novel therapies. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 102-109.	3.3	59
204	HDL-cholesterol and cardiovascular disease. Current Opinion in Cardiology, 2015, 30, 536-542.	1.8	59
205	Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. Journal of Lipid Research, 1999, 40, 648-653.	4.2	59
206	Flaxseed Reduces Plasma Cholesterol Levels in Hypercholesterolemic Mouse Models. Journal of the American College of Nutrition, 2007, 26, 66-75.	1.8	56
207	Oral Apolipoprotein Aâ€l Mimetic Dâ€4F Lowers HDLâ€Inflammatory Index in Highâ€Risk Patients: A Firstâ€inâ€Human Multipleâ€Dose, Randomized Controlled Trial. Clinical and Translational Science, 2017, 10, 455-469.	3.1	56
208	Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Current Opinion in Lipidology, 1996, 7, 117-123.	2.7	54
209	Decreased Cholesterol Efflux Capacity and Atherogenic Lipid Profile in Young Women With PCOS. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E841-E847.	3.6	54
210	From Loci to Biology. Circulation Research, 2016, 118, 586-606.	4.5	54
211	Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b) promotes hepatic glycogen synthesis and thereby regulates fasting energy homeostasis. Journal of Biological Chemistry, 2017, 292, 10444-10454.	3.4	54
212	Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. Nature Genetics, 2022, 54, 1103-1116.	21.4	54
213	Effects of Nonlipolytic Ligand Function of Endothelial Lipase on High Density Lipoprotein Metabolism in Vivo. Journal of Biological Chemistry, 2003, 278, 40688-40693.	3.4	53
214	Macrophage Reverse Cholesterol Transport in Mice Expressing ApoA-I Milano. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1496-1501.	2.4	53
215	Complete Prevention of Atherosclerosis in ApoE-Deficient Mice by Hepatic Human ApoE Gene Transfer With Adeno-Associated Virus Serotypes 7 and 8. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1852-1857.	2.4	52
216	Fine Mapping and Functional Analysis Reveal a Role of SLC22A1 in Acylcarnitine Transport. American Journal of Human Genetics, 2017, 101, 489-502.	6.2	52

DANIEL J RADER

#	Article	IF	CITATIONS
217	Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia. American Journal of Cardiology, 2015, 115, 178-182.	1.6	51
218	Loss of Cardioprotective Effects at the <i>ADAMTS7</i> Locus as a Result of Gene-Smoking Interactions. Circulation, 2017, 135, 2336-2353.	1.6	51
219	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. PLoS Medicine, 2020, 17, e1003288.	8.4	51
220	Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	51
221	Prostacylin Receptor Activation Inhibits Proliferation of Aortic Smooth Muscle Cells by Regulating cAMP Response Element-Binding Protein- and Pocket Protein-Dependent Cyclin A Gene Expression. Molecular Pharmacology, 2003, 64, 249-258.	2.3	50
222	High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis. JAMA - Journal of the American Medical Association, 2003, 290, 2322.	7.4	50
223	Fish Oil Promotes Macrophage Reverse Cholesterol Transport in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1502-1508.	2.4	50
224	Myeloid Tribbles 1 induces early atherosclerosis via enhanced foam cell expansion. Science Advances, 2019, 5, eaax9183.	10.3	50
225	Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. European Journal of Heart Failure, 2013, 15, 1215-1219.	7.1	49
226	Polygenic determinants in extremes of high-density lipoprotein cholesterol. Journal of Lipid Research, 2017, 58, 2162-2170.	4.2	49
227	Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. The Lancet Digital Health, 2019, 1, e393-e402.	12.3	49
228	Does Exercise Increase HDL Cholesterol in Those Who Need It the Most?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1097-1098.	2.4	47
229	Peroxisome Proliferator-Activated Receptor-α Activation Promotes Macrophage Reverse Cholesterol Transport Through a Liver X Receptor–Dependent Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1276-1282.	2.4	47
230	Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. Circulation, 2021, 144, 353-364.	1.6	47
231	Wild-Type ApoA-I and the Milano Variant Have Similar Abilities to Stimulate Cellular Lipid Mobilization and Efflux. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2022-2029.	2.4	46
232	CXCL12: A New Player in Coronary Disease Identified through Human Genetics. Trends in Cardiovascular Medicine, 2010, 20, 204-209.	4.9	46
233	Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. Biochemical Pharmacology, 2010, 80, 1450-1457.	4.4	46
234	LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase. Circulation Research, 2020, 127, 1112-1114.	4.5	46

#	Article	IF	CITATIONS
235	Novel congenital disorder of <i>O</i> -linked glycosylation caused by GALNT2 loss of function. Brain, 2020, 143, 1114-1126.	7.6	46
236	Multi-Ethnic Analysis of Lipid-Associated Loci: The NHLBI CARe Project. PLoS ONE, 2012, 7, e36473.	2.5	46
237	Lipoprotein(a). JAMA - Journal of the American Medical Association, 1992, 267, 1109.	7.4	45
238	Liver X Receptor and Farnesoid X Receptor as Therapeutic Targets. American Journal of Cardiology, 2007, 100, S15-S19.	1.6	45
239	Sortilin as a Regulator of Lipoprotein Metabolism. Current Atherosclerosis Reports, 2012, 14, 211-218.	4.8	45
240	Heterozygous <i>ABCG5</i> Gene Deficiency and Risk of Coronary Artery Disease. Circulation Genomic and Precision Medicine, 2020, 13, 417-423.	3.6	45
241	Hepatic Expression of Apolipoprotein E Inhibits Progression of Atherosclerosis without Reducing Cholesterol Levels in LDL Receptor-Deficient Mice. Molecular Therapy, 2000, 1, 189-194.	8.2	44
242	Endothelial Lipase: A Modulator of Lipoprotein Metabolism Upregulated by Inflammation. Trends in Cardiovascular Medicine, 2004, 14, 202-206.	4.9	44
243	Substrate specificity of lipoprotein lipase and endothelial lipase: studies of lid chimeras. Journal of Lipid Research, 2006, 47, 1803-1811.	4.2	44
244	AAV Vectors Expressing LDLR Gain-of-Function Variants Demonstrate Increased Efficacy in Mouse Models of Familial Hypercholesterolemia. Circulation Research, 2014, 115, 591-599.	4.5	44
245	Exome-wide evaluation of rare coding variants using electronic health records identifies new gene–phenotype associations. Nature Medicine, 2021, 27, 66-72.	30.7	44
246	Normal Production Rate of Apolipoprotein B in LDL Receptor–Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 989-994.	2.4	43
247	Evidence That Hepatic Lipase and Endothelial Lipase Have Different Substrate Specificities for High-Density Lipoprotein Phospholipids. Biochemistry, 2003, 42, 13778-13785.	2.5	43
248	Mining the Stiffness-Sensitive Transcriptome in Human Vascular Smooth Muscle Cells Identifies Long Noncoding RNA Stiffness Regulators. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 164-173.	2.4	43
249	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (<i>CHEK2</i>) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncology, 2019, 5, 514.	7.1	43
250	Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. American Journal of Kidney Diseases, 2019, 73, 827-836.	1.9	43
251	A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. Genetics in Medicine, 2020, 22, 102-111.	2.4	42
252	Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases. JAMA Network Open, 2021, 4, e2034461.	5.9	42

#	Article	IF	CITATIONS
253	Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase–deficient mouse adipose tissue. Journal of Clinical Investigation, 2005, 115, 161-167.	8.2	42
254	Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 140-146.	2.4	41
255	Adiponectin Is Associated with Favorable Lipoprotein Profile, Independent of BMI and Insulin Resistance, in Adolescents. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1549-1554.	3.6	41
256	Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study. European Heart Journal, 2014, 35, 2115-2122.	2.2	41
257	Antimitogenic effects of HDL and APOE mediated by Cox-2–dependent IP activation. Journal of Clinical Investigation, 2004, 113, 609-618.	8.2	41
258	The Endothelium and Lipoproteins: Insights from Recent Cell Biology and Animal Studies. Seminars in Thrombosis and Hemostasis, 2000, 26, 521-528.	2.7	40
259	Lipase H, a New Member of the Triglyceride Lipase Family Synthesized by the Intestine. Genomics, 2002, 80, 268-273.	2.9	40
260	Identification of the Active Form of Endothelial Lipase, a Homodimer in a Head-to-Tail Conformation. Journal of Biological Chemistry, 2009, 284, 23322-23330.	3.4	40
261	Genomic profiling of human vascular cells identifies TWIST1 as a causal gene for common vascular diseases. PLoS Genetics, 2020, 16, e1008538.	3.5	40
262	Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention. Trends in Molecular Medicine, 2000, 6, 170-175.	2.6	39
263	Human genetics of variation in high-density lipoprotein cholesterol. Current Atherosclerosis Reports, 2006, 8, 198-205.	4.8	39
264	The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. European Heart Journal, 2009, 30, 1584-1589.	2.2	39
265	Zinc transporter Slc39a8 is essential for cardiac ventricular compaction. Journal of Clinical Investigation, 2018, 128, 826-833.	8.2	39
266	Cytomegalovirus Latent Infection is Associated with an Increased Risk of COVID-19-Related Hospitalization. Journal of Infectious Diseases, 2022, 226, 463-473.	4.0	39
267	Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome. Circulation Research, 2014, 114, 1880-1889.	4.5	38
268	Regulated expression of endothelial lipase by porcine brain capillary endothelial cells constituting the blood-brain barrier. Journal of Neurochemistry, 2005, 94, 109-119.	3.9	37
269	Adipose Modulation of High-Density Lipoprotein Cholesterol. Circulation, 2011, 124, 1602-1605.	1.6	37
270	Disrupting upstream translation in mRNAs is associated with human disease. Nature Communications, 2021, 12, 1515.	12.8	37

#	Article	IF	CITATIONS
271	Role of fibrates in the management of hypertriglyceridemia. American Journal of Cardiology, 1999, 83, 30-35.	1.6	36
272	Endothelial Lipase Is a Critical Determinant of High-Density Lipoprotein–Stimulated Sphingosine 1-Phosphate–Dependent Signaling in Vascular Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1788-1794.	2.4	36
273	Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress. Cell Reports, 2017, 19, 1456-1466.	6.4	36
274	IL-1 and atherosclerosis: a murine twist to an evolving human story. Journal of Clinical Investigation, 2012, 122, 27-30.	8.2	36
275	Lipases as Modulators of Atherosclerosis in Murine Models. Current Drug Targets, 2007, 8, 1307-1319.	2.1	35
276	Autophagy Is Required for Sortilin-Mediated Degradation of Apolipoprotein B100. Circulation Research, 2018, 122, 568-582.	4.5	35
277	Genetic and Epigenetic Fine Mapping of Complex Trait Associated Loci in the Human Liver. American Journal of Human Genetics, 2019, 105, 89-107.	6.2	35
278	Functional validation of new pathways in lipoprotein metabolism identified by human genetics. Current Opinion in Lipidology, 2011, 22, 123-128.	2.7	34
279	Biodistribution of AAV8 Vectors Expressing Human Low-Density Lipoprotein Receptor in a Mouse Model of Homozygous Familial Hypercholesterolemia. Human Gene Therapy Clinical Development, 2013, 24, 154-160.	3.1	34
280	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovascular Research, 2019, 115, 204-212.	3.8	34
281	Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1956-1962.	2.4	33
282	Cholesteryl Ester Transfer Protein and Coronary Artery Disease. Circulation, 2004, 110, 1338-1340.	1.6	32
283	Mining the LIPG Allelic Spectrum Reveals the Contribution of Rare and Common Regulatory Variants to HDL Cholesterol. PLoS Genetics, 2011, 7, e1002393.	3.5	32
284	Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 994-1002.	2.4	32
285	A new feature on the cholesterol-lowering landscape. Nature Medicine, 2001, 7, 1282-1284.	30.7	31
286	Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA ₂ . American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E403-E411.	3.5	31
287	Targeting ApoC-III to Reduce Coronary Disease Risk. Current Atherosclerosis Reports, 2016, 18, 54.	4.8	31
288	Association of <i>APOL1</i> Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran Program. Circulation, 2019, 140, 1031-1040.	1.6	31

#	Article	IF	CITATIONS
289	High-density lipoprotein metabolism: Molecular targets for new therapies for atherosclerosis. Current Atherosclerosis Reports, 2000, 2, 363-372.	4.8	30
290	Inhibition of cholesteryl ester transfer protein activity: A new therapeutic approach to raising high-density lipoprotein. Current Atherosclerosis Reports, 2004, 6, 398-405.	4.8	30
291	Inflammation induces fibrinogen nitration in experimental human endotoxemia. Free Radical Biology and Medicine, 2009, 47, 1140-1146.	2.9	30
292	Cholesterol Efflux Capacity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1449-1451.	2.4	30
293	A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux Capacity. Journal of Proteome Research, 2018, 17, 2156-2164.	3.7	30
294	Generation of iPSCs as a Pooled Culture Using Magnetic Activated Cell Sorting of Newly Reprogrammed Cells. PLoS ONE, 2015, 10, e0134995.	2.5	30
295	Role of N-linked glycosylation in the secretion and activity of endothelial lipase. Journal of Lipid Research, 2004, 45, 2080-2087.	4.2	29
296	Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?. Current Cardiology Reports, 2012, 14, 684-691.	2.9	29
297	Potent peroxisome proliferator-activated receptor-Â agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. European Heart Journal, 2015, 36, 3020-3022.	2.2	29
298	Teaching Old Drugs New Tricks: Statins for COVID-19?. Cell Metabolism, 2020, 32, 145-147.	16.2	29
299	HDL (High-Density Lipoprotein) Subclasses, Lipid Content, and Function Trajectories Across the Menopause Transition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 951-961.	2.4	29
300	LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e57-e70.	3.6	29
301	High heritability of ascending aortic diameter and trans-ancestry prediction of thoracic aortic disease. Nature Genetics, 2022, 54, 772-782.	21.4	29
302	Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. Current Opinion in Cardiology, 2005, 20, 301-306.	1.8	28
303	Recent advances in the pharmacological management of hypercholesterolaemia. Lancet Diabetes and Endocrinology,the, 2016, 4, 436-446.	11.4	28
304	Interrogation of the Atherosclerosis-Associated <i>SORT1</i> (Sortilin 1) Locus With Primary Human Hepatocytes, Induced Pluripotent Stem Cell-Hepatocytes, and Locus-Humanized Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 76-82.	2.4	28
305	Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1. Atherosclerosis, 2006, 186, 65-73.	0.8	27
306	Accelerating the Pace of Atherosclerosis Research. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 11-12.	2.4	27

#	Article	IF	CITATIONS
307	Therapeutic Targets of Triglyceride Metabolism as Informed by Human Genetics. Trends in Molecular Medicine, 2016, 22, 328-340.	6.7	27
308	Genetics of Increased HDL Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1710-1712.	2.4	26
309	Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. Journal of Clinical Lipidology, 2016, 10, 1137-1144.e3.	1.5	26
310	Text mining applied to electronic cardiovascular procedure reports to identify patients with trileaflet aortic stenosis and coronary artery disease. Journal of Biomedical Informatics, 2017, 72, 77-84.	4.3	26
311	Apolipoprotein A-I Infusion Therapies for Coronary Disease. JAMA Cardiology, 2018, 3, 799.	6.1	26
312	N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression. Circulation, 2019, 140, 280-292.	1.6	26
313	Polygenic Risk of Psychiatric Disorders Exhibits Cross-trait Associations in Electronic Health Record Data From European Ancestry Individuals. Biological Psychiatry, 2021, 89, 236-245.	1.3	26
314	Rates of COVID-19–Related Outcomes in Cancer Compared With Noncancer Patients. JNCI Cancer Spectrum, 2021, 5, pkaa120.	2.9	26
315	Influence of Apolipoprotein A-I Domain Structure on Macrophage Reverse Cholesterol Transport in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 320-327.	2.4	25
316	ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma. Journal of Lipid Research, 2012, 53, 929-940.	4.2	25
317	Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222. Atherosclerosis, 2013, 227, 65-71.	0.8	25
318	A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease. ELife, 2021, 10, .	6.0	25
319	Upregulation of Macrophage Endothelial Lipase by Toll-Like Receptors 4 and 3 Modulates Macrophage Interleukin-10 and -12 Production. Circulation Research, 2007, 100, 1008-1015.	4.5	24
320	Association Between Genetic Variation in Blood Pressure and Increased Lifetime Risk of Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2027-2034.	2.4	24
321	Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes. American Journal of Human Genetics, 2022, 109, 81-96.	6.2	24
322	N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-l-containing high density lipoproteins. Journal of Lipid Research, 2007, 48, 2047-2057.	4.2	23
323	Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase–deficient mouse adipose tissue. Journal of Clinical Investigation, 2005, 115, 161-167.	8.2	23
324	Clinical Implications of Lipid Genetics for Cardiovascular Disease. Current Cardiovascular Risk Reports, 2010, 4, 461-468.	2.0	22

#	Article	IF	CITATIONS
325	A novel approach to measuring macrophage-specific reverse cholesterol transport in vivo in humans. Journal of Lipid Research, 2017, 58, 752-762.	4.2	22
326	Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration. JCI Insight, 2021, 6, .	5.0	22
327	Apolipoprotein E and Coronary Disease: A Puzzling Paradox. PLoS Medicine, 2006, 3, e258.	8.4	21
328	Directional ABCA1-mediated cholesterol efflux and apoB-lipoprotein secretion in the retinal pigment epithelium. Journal of Lipid Research, 2018, 59, 1927-1939.	4.2	21
329	Antiâ€Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. Journal of the American Heart Association, 2020, 9, e016507.	3.7	21
330	A tetracycline-regulated adenoviral expression system forin vivo delivery of transgenes to lung and liver. Journal of Gene Medicine, 2003, 5, 567-575.	2.8	20
331	Endocannabinoid Antagonism: Blocking the Excess in the Treatment of High-Risk Abdominal Obesity. Trends in Cardiovascular Medicine, 2007, 17, 35-43.	4.9	20
332	Lecithin: Cholesterol Acyltransferase and Atherosclerosis. Circulation, 2009, 120, 549-552.	1.6	20
333	Tribbles-1: a novel regulator of hepatic lipid metabolism in humans. Biochemical Society Transactions, 2015, 43, 1079-1084.	3.4	20
334	Discovery and Validation of New Molecular Targets in Treating Dyslipidemia: The Role of Human Genetics. Trends in Cardiovascular Medicine, 2009, 19, 195-201.	4.9	19
335	PPARÎ ³ activation redirects macrophage cholesterol from fecal excretion to adipose tissue uptake in mice via SR-BI. Biochemical Pharmacology, 2011, 81, 934-941.	4.4	19
336	Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. Frontiers in Immunology, 2021, 12, 650465.	4.8	19
337	Endothelial lipase is less effective at influencing HDL metabolism in vivo in mice expressing apoA-II. Journal of Lipid Research, 2006, 47, 2191-2197.	4.2	18
338	Cholesteryl Ester Transfer Protein (CETP) Inhibitors: Is There Life After Torcetrapib?. Cardiology Clinics, 2008, 26, 537-546.	2.2	18
339	Polyphenols and Cholesterol Efflux. Circulation Research, 2010, 106, 627-629.	4.5	18
340	Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins. PLoS Genetics, 2021, 17, e1009802.	3.5	18
341	Therapy to reduce risk of coronary heart disease. Clinical Cardiology, 2003, 26, 2-8.	1.8	17
342	Secreted miRNAs suppress atherogenesis. Nature Cell Biology, 2012, 14, 233-235.	10.3	17

#	Article	IF	CITATIONS
343	Beyond LDL Cholesterol in Assessing Cardiovascular Risk: apo B or LDL-P?. Clinical Chemistry, 2013, 59, 723-725.	3.2	17
344	Apolipoprotein A-I and Cholesterol Efflux. Circulation Research, 2014, 114, 1681-1683.	4.5	17
345	New insights into the role of glycosylation in lipoprotein metabolism. Current Opinion in Lipidology, 2017, 28, 502-506.	2.7	17
346	Genetics of Postlingual Sensorineural Hearing Loss. Laryngoscope, 2021, 131, 401-409.	2.0	17
347	Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. European Urology, 2022, 81, 559-567.	1.9	17
348	'Multipurpose oxidase' in atherogenesis. Nature Medicine, 2007, 13, 1146-1147.	30.7	16
349	Prediabetic Obese Adolescents have a More Atherogenic Lipoprotein Profile Compared with Normoglycemic Obese Peers. Journal of Pediatrics, 2012, 161, 881-886.	1.8	16
350	Mighty Minipig in Fight Against Cardiovascular Disease. Science Translational Medicine, 2013, 5, 166fs1.	12.4	16
351	Spotlight on HDL biology: new insights in metabolism, function, and translation. Cardiovascular Research, 2014, 103, 337-340.	3.8	16
352	Genomic Risk Stratification Predicts All-Cause Mortality After Cardiac Catheterization. Circulation Genomic and Precision Medicine, 2018, 11, e002352.	3.6	16
353	Manganese homeostasis: from rare single-gene disorders to complex phenotypes and diseases. Journal of Clinical Investigation, 2019, 129, 5082-5085.	8.2	16
354	Structure–function properties of the apoE-dependent COX-2 pathway in vascular smooth muscle cells. Atherosclerosis, 2008, 196, 201-209.	0.8	15
355	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. PLoS ONE, 2020, 15, e0237430.	2.5	15
356	Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids. Cell Metabolism, 2021, 33, 1592-1609.e7.	16.2	15
357	Novel ENU-Induced Point Mutation in Scavenger Receptor Class B, Member 1, Results in Liver Specific Loss of SCARB1 Protein. PLoS ONE, 2009, 4, e6521.	2.5	15
358	Glycosylation of endothelial lipase at asparagine-116 reduces activity and the hydrolysis of native lipoproteins in vitro and in vivo. Journal of Lipid Research, 2007, 48, 1132-1139.	4.2	14
359	Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers. Expert Review of Cardiovascular Therapy, 2008, 6, 1007-1022.	1.5	14
360	Shortâ€Term Treatment with Highâ€Dose Atorvastatin Reduces LDL Cholesterol but Shows no Antiâ€Inflammatory Effects in Normolipidemic Subjects with Normal CRP Levels. Clinical and Translational Science, 2010, 3, 140-146.	3.1	14

DANIEL J RADER

#	Article	IF	CITATIONS
361	Mendelian Randomization Analysis of Hemostatic Factors and Their Contribution to Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 41, 380-386.	2.4	14
362	Quantification of abdominal fat from computed tomography using deep learning and its association with electronic health records in an academic biobank. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1178-1187.	4.4	14
363	Structural basis of endothelial lipase tropism for HDL. FASEB Journal, 2004, 18, 1891-1893.	0.5	13
364	Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. Clinical Lipidology, 2010, 5, 793-809.	0.4	13
365	Genetics of Lipid Traits and Relationship to Coronary Artery Disease. Current Cardiology Reports, 2013, 15, 396.	2.9	13
366	Inhibition of Endothelial Lipase Activity by Sphingomyelin in the Lipoproteins. Lipids, 2014, 49, 987-996.	1.7	13
367	Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport. Journal of Lipid Research, 2017, 58, 731-741.	4.2	13
368	"Phenoâ€menal value for human health. Science, 2016, 354, 1534-1536.	12.6	12
369	Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation, 2016, 35, 1295-1302.	0.6	12
370	Could Exercise Metabolomics Pave the Way for Gymnomimetics?. Science Translational Medicine, 2010, 2, 41ps35.	12.4	11
371	Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics. Clinical Lipidology, 2013, 8, 635-648.	0.4	11
372	A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production. Atherosclerosis, 2014, 235, 470-476.	0.8	11
373	Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution. Atherosclerosis, 2016, 250, 63-68.	0.8	11
374	ILRUN, a Human Plasma Lipid GWAS Locus, Regulates Lipoprotein Metabolism in Mice. Circulation Research, 2020, 127, 1347-1361.	4.5	11
375	A randomized controlled trial of genetic testing and cascade screening in familial hypercholesterolemia. Genetics in Medicine, 2021, 23, 1697-1704.	2.4	11
376	MitoScape: A big-data, machine-learning platform for obtaining mitochondrial DNA from next-generation sequencing data. PLoS Computational Biology, 2021, 17, e1009594.	3.2	11
377	Sortilin restricts secretion of apolipoprotein B-100 by hepatocytes under stressed but not basal conditions. Journal of Clinical Investigation, 2022, 132, .	8.2	11
378	Lipoprotein(a) levels and heart transplantation atherosclerosis. American Heart Journal, 1998, 136, 329-334.	2.7	10

#	Article	IF	CITATIONS
379	Rare, Damaging DNA Variants in <i>CORIN</i> and Risk of Coronary Artery Disease: Insights From Functional Genomics and Large-Scale Sequencing Analyses. Circulation Genomic and Precision Medicine, 2021, 14, e003399.	3.6	10
380	Genetics of lipid traits: Genome-wide approaches yield new biology and clues to causality in coronary artery disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2010-2020.	3.8	9
381	Cardiovascular prevention—end of the road for niacin?. Nature Reviews Endocrinology, 2014, 10, 646-647.	9.6	9
382	Lipidomic Analyses of Female Mice Lacking Hepatic Lipase and Endothelial Lipase Indicate Selective Modulation of Plasma Lipid Species. Lipids, 2014, 49, 505-515.	1.7	9
383	Human Genetics of Atherothrombotic Disease and its Risk Factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 741-747.	2.4	9
384	Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome. Journal of Clinical Lipidology, 2017, 11, 1192-1200.e3.	1.5	9
385	TRIB1 regulates LDL metabolism through CEBPα-mediated effects on the LDL receptor in hepatocytes. Journal of Clinical Investigation, 2021, 131, .	8.2	9
386	The Relationship Between Lipoproteins and Insulin Sensitivity in Youth With Obesity and Abnormal Glucose Tolerance. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1541-1551.	3.6	9
387	Endothelial plasticity drives aberrant vascularization and impedes cardiac repair after myocardial infarction. , 2022, 1, 372-388.		9
388	Nuclear Receptors and microRNA-144 Coordinately Regulate Cholesterol Efflux. Circulation Research, 2013, 112, 1529-1531.	4.5	8
389	Expression of Type IIA Secretory Phospholipase A ₂ Inhibits Cholesteryl Ester Transfer Protein Activity in Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2707-2714.	2.4	8
390	Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin. Journal of the American Heart Association, 2018, 7, e03488.	3.7	8
391	Annual Report on Sex in Preclinical Studies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, e1-e9.	2.4	8
392	EDEM3 Modulates Plasma Triglyceride Level through Its Regulation of LRP1 Expression. IScience, 2020, 23, 100973.	4.1	8
393	Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation. Cardiology Clinics, 2003, 21, 377-392.	2.2	7
394	Gene therapy for lipoprotein disorders. Expert Opinion on Biological Therapy, 2005, 5, 1029-1038.	3.1	7
395	When HDL Gets Fat …. Circulation Research, 2008, 103, 131-132.	4.5	7
396	Opposing Effects of ABCG5/8 Function on Myocardial Infarction and Gallstone Disease. Journal of the American College of Cardiology, 2014, 63, 2129-2130.	2.8	7

#	Article	IF	CITATIONS
397	Genome-first approach to rare EYA4 variants and cardio-auditory phenotypes in adults. Human Genetics, 2021, 140, 957-967.	3.8	7
398	Implementation of a Machine-Learning Algorithm in the Electronic Health Record for Targeted Screening for Familial Hypercholesterolemia: A Quality Improvement Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007641.	2.2	7
399	Impact of natural selection on global patterns of genetic variation and association with clinical phenotypes at genes involved in SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2123000119.	7.1	7
400	Current drug options for raising HDL cholesterol. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 15-23.	0.9	6
401	Lymphatics as a New Active Player in Reverse Cholesterol Transport. Cell Metabolism, 2013, 17, 627-628.	16.2	6
402	Selfâ€Organizing Human Induced Pluripotent Stem Cell Hepatocyte 3D Organoids Inform the Biology of the Pleiotropic TRIB1 Gene. Hepatology Communications, 2020, 4, 1316-1331.	4.3	6
403	Nuclear receptors FXR and SHP regulate protein N-glycan modifications in the liver. Science Advances, 2021, 7, .	10.3	6
404	Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Clinically Observed Longitudinal Cholesterol Exposure. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003501.	3.6	6
405	ATVB In Focus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 480-481.	2.4	5
406	Mediterranean Approach to Improving High-Density Lipoprotein Function. Circulation, 2017, 135, 644-647.	1.6	5
407	Multiplexed Targeted Resequencing Identifies Coding and Regulatory Variation Underlying Phenotypic Extremes of High-Density Lipoprotein Cholesterol in Humans. Circulation Genomic and Precision Medicine, 2018, 11, e002070.	3.6	5
408	Associations of Endogenous Hormones With HDL Novel Metrics Across the Menopause Transition: The SWAN HDL Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e303-e314.	3.6	5
409	Deep Apolipoprotein Proteomics toÂUncover Mechanisms of CoronaryÂDiseaseÂRisk â^—. Journal of the American College of Cardiology, 2017, 69, 801-804.	2.8	4
410	Lipid droplet screen in human hepatocytes identifies TRRAP as a regulator of cellular triglyceride metabolism. Clinical and Translational Science, 2021, 14, 1369-1379.	3.1	4
411	A genome-first approach to rare variants in hypertrophic cardiomyopathy genes <i>MYBPC3</i> and <i>MYH7</i> in a medical biobank. Human Molecular Genetics, 2022, 31, 827-837.	2.9	4
412	Genomic medicine in the prevention and treatment of atherosclerotic cardiovascular disease. Personalized Medicine, 2012, 9, 395-404.	1.5	3
413	Improving cardiovascular outcomes by intensifying low density lipoprotein lowering therapy in high-risk patients. European Heart Journal, 2016, 37, 3585-3587.	2.2	3
414	Antisense oligonucleotides for atherosclerotic disease. Nature Medicine, 2020, 26, 471-472.	30.7	3

#	Article	IF	CITATIONS
415	A Genomeâ€First Approach to Rare Variants in Dominant Postlingual Hearing Loss Genes in a Large Adult Population. Otolaryngology - Head and Neck Surgery, 2022, 166, 746-752.	1.9	3
416	Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease. Molecules, 2021, 26, 6862.	3.8	3
417	Multi-Trait Genome-Wide Association Study of Atherosclerosis Detects Novel Pleiotropic Loci. Frontiers in Genetics, 2021, 12, 787545.	2.3	3
418	Lipoprotein Physiology. Contemporary Endocrinology, 2015, , 1-12.	0.1	2
419	Intracoronary Imaging, Reverse Cholesterol Transport, and Transcriptomics. Journal of the American College of Cardiology, 2017, 69, 641-643.	2.8	2
420	Soluble FMS-Like Tyrosine Kinase-1 Is a Circulating Biomarker Associated With Calcific Aortic Stenosis. Journal of the American College of Cardiology, 2019, 73, 1364-1365.	2.8	2
421	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. JCO Oncology Practice, 2021, 17, e1879-e1886.	2.9	2
422	Web of Science's Citation Median Metrics Overcome the Major Constraints of the Journal Impact Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 367-371.	2.4	2
423	Associations of Abdominal and Cardiovascular Adipose Tissue Depots With HDL Metrics in Midlife Women: the SWAN Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2245-e2257.	3.6	2
424	ILRUN Promotes Atherosclerosis Through Lipid-Dependent and Lipid-Independent Factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 0, , .	2.4	2
425	Endothelial Lipase: A Novel Drug Target for HDL and Atherosclerosis?. , 2005, , 139-153.		1
426	Lipoprotein Disorders. , 2010, , 269-288.		1
427	Can changes in the plasma lipidome help explain the cardiovascular benefits of the Mediterranean diet?. American Journal of Clinical Nutrition, 2017, 106, 965-966.	4.7	1
428	Lipoprotein Disorders. , 2018, , 27-46.		1
429	FP526VASCULAR CXCR4 LIMITS ATHEROSCLEROSIS BY MAINTAINING ARTERIAL INTEGRITY. Nephrology Dialysis Transplantation, 2018, 33, i216-i216.	0.7	1
430	Atherogenic Lipid Metabolism in Obesity. , 2011, , 293-309.		1
431	Genetic Disorders of Lipoprotein Metabolism. , 2007, , 23-35.		1
432	Anti-Inflammatory and Antioxidant Functions of High Density Lipoproteins. , 2006, , 399-436.		0

#	Article	IF	CITATIONS
433	Lipoprotein Disorders. , 2013, , 501-515.		0
434	2003 Mixed meal effects of neprilysin inhibition. Journal of Clinical and Translational Science, 2018, 2, 44-44.	0.6	0
435	Lack of pathogenic germline DICER1 variants in males with testicular germ-cell tumors. Cancer Genetics, 2020, 248-249, 49-56.	0.4	0
436	4365 Family-Based Study of Sleep in Autism Spectrum Disorder without Intellectual Disability. Journal of Clinical and Translational Science, 2020, 4, 72-72.	0.6	0
437	Systematically Sifting Big Data to Identify Novel Causal Genes for Human Traits. Cell Metabolism, 2020, 31, 658-659.	16.2	0
438	Hepatic Manifestations of Mendelian Disorders of Cholesterol Biosynthesis and Cellular Metabolism. Clinical Liver Disease, 2021, 18, 266-273.	2.1	0
439	Therapeutic Targeting of High-Density Lipoprotein Metabolism. , 2009, , 544-552.		0
440	Lipoprotein Disorders. , 2009, , 634-651.		0
441	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. , 2020, 17, e1003288.		0
442	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. , 2020, 17, e1003288.		0
443	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. , 2020, 17, e1003288.		0
444	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. , 2020, 17, e1003288.		0
445	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. , 2020, 17, e1003288.		0